



Agenda

This is a draft agenda and subject to change.

Wednesday, **August 19, 2026 – 8 a.m.**

Register for meeting: [Zoom link](#)

Table 1 Board agenda details.

Subject	Presenter	Purpose
Call to order and roll call	Chair Shelley Bailey	<i>Informational and vote</i>
Board declarations of conflict of interest and meetings with entities or individuals related to board activities	Chair Shelley Bailey	<i>Informational</i>
<u>Board review of 7/15/2026 minutes</u>	Chair Shelley Bailey	<i>Review</i>
PDAB program update	Sarah Young, executive director	<i>Informational</i>
General and drug review public comment periods: limited to 3 minutes per speaker	Chair Shelley Bailey	<i>Informational</i>
<u>Drug review: Ocrevus, Skyrizi, Tremfya, Xolair</u>	PDAB Staff	<i>Informational</i>
The board will take a break around 10 a.m.	Chair Shelley Bailey	<i>Break</i>
Announcements	Chair Shelley Bailey	<i>Informational</i>
Adjournment	Chair Shelley Bailey	<i>Vote</i>

Accessibility: Anyone needing assistance due to a disability or language barrier can contact Melissa Stiles at least 48 hours ahead of the meeting at pdab@dcbs.oregon.gov or 971-374-3724. American Sign Language will be available during the August 19 board meeting.



Oregon Prescription Drug Affordability Board Regular Meeting
Wednesday, July 15, 2026
Draft Minutes

Web link to the meeting video: <https://youtu.be/kSp5erHOLtk>

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20260715-PDAB-document-package.pdf>

Call to order: Vice Chair Dan Hartung called the meeting to order at 8:02 a.m.

Roll call:

Present: Vice Chair Dan Hartung, Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Noelle Redmond

Absent: Chair Shelley Bailey

New board member: Vice Chair Hartung introduced and welcomed new board member Noelle Redmond, who is the director of clinical pharmacy services at Cambia Health Solutions/Regence Blue Cross Blue Shield in Portland. View at video minute [00:01:00](#).

Board declarations of conflict of interest and meetings with entities or individuals related to board activities: John Murray, Chris Laman, and Dan Hartung provided statements. View at video minute [00:01:57](#).

Approval of board minutes: Vice Chair Hartung approved by consensus the corrected minutes of June 17, 2026, as shown on [Pages 2-3](#) of the agenda materials. Staff corrected a misspelled name in the board declaration section of the minutes and added a note about the correction. View at video minute [00:04:09](#).

PDAB program update: Sarah Young, PDAB executive director, provided a program update. View at video minute [00:05:15](#).

General and drug review public comment periods: Charlie Fisher of OSPIRG and MaryAnne Cooper of Regence BlueCross Blue Shield of Oregon, provided general public comments for the board. View at video minute [00:11:26](#). The board received [one written general comment](#). During the drug review comment period, Lorren Sandt of Caring Ambassadors Program, and Terri Lee of Merck, spoke about Keytruda. View at video minute [00:19:39](#). The board received [seven drug review written comments](#).

Oregon insurance regulation presentation: Numi Lee Griffith, senior policy advisor with the Division of Financial Regulation, provided a presentation about Oregon insurance regulation. View the slides on [Pages 4-22](#). View the presentation at video minute [00:28:05](#).



Drug review: Keytruda, Verzenio, and Xeljanz: Cortnee Whitlock, PDAB program and senior policy analyst, presented the drug review reports, followed by board discussion. They began by reviewing and discussing the [2026 drug review roadmap](#) and [scoring rubric options](#). View the roadmap and scoring rubric discussion at video minute [01:13:11](#). View the [Keytruda](#) discussion at video minute [01:37:09](#). View the [Verzenio](#) discussion at video minute [02:03:44](#). View the [Xeljanz](#) discussion at video minute [02:13:05](#).

Board discussion: policy concepts for annual report: Cortnee Whitlock presented slides with policy concepts for consideration to prioritize and research, followed by board discussion. The board identified four concepts to research for further discussion. View the slides on [Pages 31-41](#). View at video minute [02:39:18](#).

Announcements: Vice Chair Hartung announced the next board meeting will be August 19, 2026, at 8 a.m. View at video minute [03:36:20](#).

Adjournment: Vice Chair Hartung adjourned the meeting at 11:43 a.m. with all board members in agreement. View at video minute [03:36:37](#).



Oregon Prescription Drug
Affordability Board



Prescription Drug Affordability Board

2026 Drug review roadmap

August 19, 2026

Drug review & annual report calendar


(This is a rolling document and subject to change)




2026 Preliminary Rx and insulin subset list



2026 Policy recommendations




Data call & APAC information of Rx subset list



Public outreach and events



Public online feedback forms



Annual report (includes recommendations and generic drug report)





Oregon Prescription Drug Affordability Board

Table 1 on this page was updated Aug. 12, 2026 to include additional clinical reviews and an updated Skyrizi drug review report.

Web links to 2026 drug review reports and data

Agenda item: Drug review: Ocrevus, Skyrizi, Tremfya, and Xolair.

Here is a link to a data summary document: [Statewide reference for 2024 data](#).

Table 1 provides links to the 2026 Oregon PDAB drug review reports and data. Drug review reports will be posted on the PDAB website one week before the meeting. Videos will be posted soon after the board meeting. Meeting minutes will be posted the day of board approval. Click on the direct links in Table 1 or find the drug reports on the [PDAB drug review page](#) and the data information on the [PDAB data page](#).

Table 1

Meeting date	Drug review report	Data links	Meeting video	Meeting minutes
June 17, 2026	• Jardiance • Mounjaro • Ozempic • Humulin R U-500	• 2026 Drug Review Subset List v01 • 2026 Insulin Review Subset List v01	June 17, 2026	June 17, 2026
July 15, 2026	• Keytruda • Verzenio • Xeljanz		July 15, 2026	July 15, 2026
Aug. 19, 2026	• Ocrevus ○ Ocrevus clinical review ○ Rituxan as Ocrevus Therapeutic Alternative • Skyrizi ○ Skyrizi clinical review • Tremfya ○ Tremfya clinical review • Xolair ○ Xolair clinical review		Aug. 19, 2026	Aug. 19, 2026